Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects on its future potential, where enrollment predictability may be the biggest prize of all.
|Articles|August 7, 2007
Quebec City in 1994, Montreal in 2001, and Toronto in 2007!
Quebec City in 1994, Montreal in 2001 and Toronto in 2007!
Advertisement
TORONTO, CANADA, July 26, 2007-Over the past fourteen years Anapharm has established itself as a world class provider of clinical and bioanalytical services to international sponsors and offers strategically located operations in five Canadian cities. Most recently, we opened a 160-bed clinical facility in Toronto, Canada.
Toronto site features:
- Modern, efficient facilities;
- Over 40,000 sq ft, on the 6th floor with ample natural light and park views;
- Clinical site comprised of 4 spacious clinical units with a total capacity of 160 beds;
- Units can be combined in order to conduct larger studies;
- The clinic offers full clinical services and on-site Quality Assurance support. Project Management services continue to be offered at the same level of excellence as at our Quebec and Montreal sites. One of our bioanalytical sites is located nearby in Richmond Hill.
Advertisement
Related to this article
In this video interview, Carole Berini, PhD, of Ontada, explains how validated proxies for variables like ECOG performance status can recover not just sample size but the representativeness of hard-to-reach patient populations in real-world oncology studies.
A biomarker test now decides who enters a precision medicine trial, yet results often go unused and assays are not ready when screening opens.
In today's ACT Brief, we examine proportionate analysis frequency in RBQM, how to build trust into real-world evidence foundations for cancer trials, and how rare disease developers monetize regulatory success.
Real-time RBQM requires proportionate analysis frequency matched to data arrival and issue criticality, not continuous reanalysis, because signal churn from over-frequent runs creates alert fatigue and operational noise that obscures meaningful deterioration.
In this video interview, Saamir Pasha and Carole Berini, PhD, of Ontada, explain how building trust into the data foundation—through source lineage, standardization, and reconciliation—is what makes reliable real-world evidence generation in oncology possible.
In today's ACT Brief, we examine how AI surfaces design flaws before enrollment, why site training readiness depends on learning science, and the priorities defining next-generation weight-loss therapies.
Site training effectiveness depends on readiness at first-patient-in, requiring learning-science design principles around performance focus, cognitive load reduction, progressive sequencing, and spaced retrieval practice rather than training completion metrics or content volume.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Real-Time Data, Right-Time Decisions: Rethinking Analysis Frequency in RBQM
2
What It Takes to Harmonize AI Across Fragmented Oncology Health Systems
3
FDA Releases Transparency Roadmap Outlining Disclosure Priorities Across Drug Development and Regulatory Review
4
ACT Brief: FDA Transparency Roadmap, Radiopharmaceutical Trial Operations, and AI-Powered Enrollment Prediction
5